Company news
Soleno Therapeutics, Inc. (NASDAQ:SLNO) news
Every Soleno Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
Soleno Therapeutics to Participate in the BIO CEO & Investor Conference
February 7, 2022
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
January 23, 2022
Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event
January 4, 2022
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 9, 2021
Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021
Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 15, 2021
Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR
September 7, 2021
Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a
June 1, 2021
Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021
May 20, 2021
Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit
May 19, 2021
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 4, 2021
Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome
May 3, 2021
Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall
April 13, 2021
Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference
March 8, 2021
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
March 2, 2021
Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases
February 22, 2021
Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome
February 4, 2021
Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi Syndrome
January 27, 2021
Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
January 3, 2021
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
November 9, 2020
Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome
November 2, 2020
Soleno Therapeutics Announces Late-Breaking Oral Presentation with Body Composition Results from Phase III DESTINY PWS Trial of DCCR in Prader-Willi Syndrome at ObesityWeek® 2020 Meeting
October 28, 2020
Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
September 29, 2020
Soleno Therapeutics to Participate in Fireside Chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 14, 2020
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results
August 9, 2020
Soleno Therapeutics Added to Russell 3000® Index
June 28, 2020
Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 25, 2020
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
June 23, 2020
Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
June 7, 2020
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
May 11, 2020
Soleno Therapeutics Announces Publication Evaluating Potential Role of Activating ATP-Sensitive Potassium Channel in Treatment of Hyperphagic Obesity
April 22, 2020
Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference
March 10, 2020
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
March 3, 2020
Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
January 5, 2020
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results
November 12, 2019
Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock
October 24, 2019
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
October 22, 2019
Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome
October 1, 2019
Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome
September 23, 2019
Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies
September 18, 2019